Vaccine CDMO Market Key Players, Trends & Forecast to 2030
The global vaccine
CDMO market is projected to grow at an annual rate
of 8% over the next five years. Key drivers include the rising demand for
vaccines, expanding collaborations between biopharmaceutical companies and
government bodies with CDMOs, advancements in vaccine production technologies,
and a growing need for specialized CDMO services to support emerging vaccine
innovations. Additionally, increased private and public investment in vaccine
CDMOs, along with a rising trend of outsourcing to cut costs and speed up
time-to-market, are fueling market growth.
Year-End
Mega Sale: Get Up to 10% Off on All Market Research Reports!
A Vaccine Contract Development and Manufacturing
Organization (CDMO) offers outsourced services for the development, production,
and commercialization of vaccines. These organizations partner with
pharmaceutical and biotech companies, providing comprehensive solutions that
span process development, drug substance manufacturing, fill-finish, packaging,
and regulatory compliance. Vaccine CDMOs specialize in cutting-edge
technologies, including mRNA, viral vectors, recombinant proteins, and
inactivated vaccines, helping clients scale production quickly and efficiently.
They are vital in expediting vaccine development, particularly during global
health crises, by offering flexible, high-capacity manufacturing capabilities.
Competitive Landscape Analysis
The global vaccine CDMO market is marked by the presence
of established and emerging market players such as Lonza
Group, Thermo Fisher Scientific, Catalent, Inc, Samsung Biologics, CordenPharma, WuXi Vaccines, Recipharm AB, ICON plc, FUJIFILM Diosynth Biotechnologies, and Curia Global, Inc.; among others. Some of the
key strategies adopted by market players include new product development,
strategic partnerships and collaborations, and geographic expansion.
Rising
Vaccine Demand Boosts Market Growth
The growing demand for vaccines—driven by infectious disease outbreaks,
expanding immunization programs, and advancements in mRNA technology—is
accelerating the vaccine CDMO market. Biopharma companies are increasingly
outsourcing manufacturing to CDMOs to scale production, cut costs, and navigate
complex regulatory landscapes. The success of COVID-19 mRNA vaccines has
significantly boosted demand for CDMOs with expertise in lipid nanoparticle
(LNP) formulation and cold chain logistics. Additionally, global vaccine
initiatives and government partnerships are securing long-term contracts for
CDMOs, prompting major players to ramp up manufacturing capacity to meet the
escalating global vaccine demand.
Download Sample Copy: https://meditechinsights.com/vaccine-cdmo-market/request-sample/
Technological
Advancements Fuel Market Expansion
Innovations in vaccine manufacturing technologies, including mRNA, viral
vectors, cell-based production, and single-use bioreactors, are driving growth
in the Vaccine CDMO market. These advancements require specialized knowledge
and infrastructure, pushing biopharma companies to outsource production to
CDMOs with cutting-edge capabilities. Breakthroughs in mRNA vaccines,
particularly in LNP formulation and enzymatic synthesis, have further increased
demand for CDMO services. Meanwhile, automation, continuous manufacturing, and
AI-driven process optimization are enhancing production efficiency. Leading
CDMOs are focusing on next-generation vaccine technologies, accelerating global
vaccine availability and commercialization.
Global Vaccine CDMO Market
Segmentation
This report by Medi-Tech Insights provides
the size of the global vaccine CDMO market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on vaccine type, phase, end user.
Market Size & Forecast (2023-2030), By Vaccine Type,
USD Million
·
mRNA
Vaccines
·
Viral
Vector Vaccines
·
Recombinant
Protein Vaccines
·
Inactivated
& Live-Attenuated Vaccines
·
Conjugate
& Toxoid Vaccines
·
DNA
Vaccines
·
Others
Market Size & Forecast (2023-2030), By Phase, USD
Million
·
Pre-clinical
·
Clinical
·
Commercial
Market Size & Forecast (2023-2030), By End User, USD
Million
·
Biopharmaceutical
& Vaccine Developers
·
Government
& Public Health Agencies
·
Others
Market Size & Forecast (2023-2030), By Region, USD
Million
·
North
America
o US
o Canada
·
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
·
Asia
Pacific
o China
o India
o Japan
o Rest of Asia Pacific
·
Latin
America
·
Middle East
& Africa
Browse Report: https://meditechinsights.com/vaccine-cdmo-market/
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79

Comments
Post a Comment